<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 30.3 - Aplastic Anaemia [SDL]</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 30.3 - Aplastic Anaemia [SDL] | MD3 SCP Cases">
  <meta name="description" content="Self-directed learning on aplastic anaemia: pancytopenia, bone marrow failure, causes, severity classification, and management including HSCT and immunosuppression. A haematological emergency.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:title" content="Case 30.3 - Aplastic Anaemia [SDL]">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="Self-directed learning on aplastic anaemia: pancytopenia, bone marrow failure, causes, severity classification, and management including HSCT and immunosuppression. A haematological emergency.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 30.3 – Aplastic Anaemia [SDL]</h1>
    <p class="meta"><strong>Category:</strong> Medicine | <strong>Discipline:</strong> Haematology | <strong>Week:</strong> 30</p>

    <h2>Self-Directed Learning Overview</h2>
    <p>This self-directed learning case focuses on <strong>Aplastic Anaemia</strong>, a rare but serious condition characterized by pancytopenia (reduction in all blood cell lines) due to bone marrow failure. Understanding this condition is crucial as it represents a haematological emergency requiring prompt recognition and specialist management.</p>

    <h2>Learning Objectives</h2>
    <p>By the end of this SDL session, you should be able to:</p>
    <ul>
      <li>Define aplastic anaemia and explain its pathophysiology</li>
      <li>Identify the causes of aplastic anaemia (acquired vs inherited)</li>
      <li>Recognize the clinical presentation and examination findings</li>
      <li>Interpret the key investigation findings including blood film and bone marrow biopsy</li>
      <li>Understand the severity classification and its prognostic significance</li>
      <li>Outline the management options including supportive care, immunosuppression, and stem cell transplantation</li>
      <li>Recognize the complications and understand the importance of early specialist referral</li>
    </ul>

    <h2>Case Scenario</h2>
    <p>A 32-year-old woman, Ms. Sarah Thompson, presents to the Emergency Department with a 3-week history of progressive fatigue, recurrent nosebleeds, and easy bruising. She has also noticed increased frequency of infections over the past month. She denies any significant past medical history but mentions she recently completed a course of chloramphenicol for a presumed bacterial infection 6 weeks ago.</p>

    <div class="vital-signs">
      <strong>On Examination:</strong>
      <ul>
        <li>General: Pale, multiple bruises on limbs</li>
        <li>ENT: Petechiae on soft palate, dried blood in nares</li>
        <li>Cardiovascular: Tachycardic (HR 110 bpm), flow murmur</li>
        <li>Respiratory: Clear chest</li>
        <li>Abdomen: No hepatosplenomegaly, no lymphadenopathy</li>
        <li>Skin: Petechiae and ecchymoses, no rash</li>
      </ul>
    </div>

    <h2>Initial Investigations</h2>
    <div class="investigation-results">
      <strong>Full Blood Count:</strong>
      <ul>
        <li>Hb: 62 g/L (normal 115-165 g/L)</li>
        <li>WCC: 1.8 × 10⁹/L (normal 4-11 × 10⁹/L)</li>
        <li>Neutrophils: 0.4 × 10⁹/L (normal 2-7.5 × 10⁹/L) - <strong>Severe neutropenia</strong></li>
        <li>Platelets: 12 × 10⁹/L (normal 150-400 × 10⁹/L) - <strong>Severe thrombocytopenia</strong></li>
        <li>Reticulocytes: 8 × 10⁹/L (normal 50-100 × 10⁹/L) - <strong>Low (inappropriately low response to anaemia)</strong></li>
      </ul>
      <strong>Blood Film:</strong> Pancytopenia with no abnormal cells. Red cells normocytic normochromic. No blasts seen.
      <br><strong>Bone Marrow Biopsy:</strong> Hypocellular marrow with <10% cellularity. Reduced megakaryocytes, erythroid and myeloid precursors. Increased fat spaces. No malignant infiltration or fibrosis.
    </div>

    <h2>Key Topics to Explore</h2>

    <div class="question">
      <h3>1. Definition and Pathophysiology</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Definition:</strong></p>
        <p>Aplastic anaemia is a condition characterized by <strong>pancytopenia</strong> (anaemia, leukopenia, and thrombocytopenia) resulting from <strong>bone marrow failure</strong> with reduced or absent haematopoietic precursors, leading to hypocellular bone marrow.</p>

        <p><strong>Pathophysiology:</strong></p>
        <p>The underlying mechanism involves:</p>
        <ul>
          <li><strong>Destruction of haematopoietic stem cells:</strong> Usually T-cell mediated autoimmune destruction of pluripotent stem cells</li>
          <li><strong>Impaired stem cell function:</strong> Reduced proliferation and differentiation capacity</li>
          <li><strong>Abnormal bone marrow microenvironment:</strong> Defective stromal support for haematopoiesis</li>
        </ul>

        <p>This results in:</p>
        <ul>
          <li>Reduction in all three blood cell lines (red cells, white cells, platelets)</li>
          <li>Hypocellular bone marrow replaced by fatty tissue</li>
          <li>Normal remaining cells (unlike dysplastic changes in myelodysplasia)</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>2. Aetiology and Causes</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Acquired Aplastic Anaemia (majority of cases):</strong></p>

        <table>
          <tr>
            <th>Category</th>
            <th>Examples</th>
          </tr>
          <tr>
            <td><strong>Idiopathic</strong></td>
            <td>70% of cases - no identifiable cause</td>
          </tr>
          <tr>
            <td><strong>Drugs</strong></td>
            <td>
              <strong>Predictable dose-related:</strong> Chemotherapy, radiotherapy<br>
              <strong>Idiosyncratic:</strong> Chloramphenicol, NSAIDs, gold, penicillamine, sulfonamides, carbimazole, phenytoin
            </td>
          </tr>
          <tr>
            <td><strong>Chemicals/Toxins</strong></td>
            <td>Benzene, insecticides, organic solvents</td>
          </tr>
          <tr>
            <td><strong>Viral Infections</strong></td>
            <td>
              Epstein-Barr virus (EBV), cytomegalovirus (CMV), HIV, hepatitis viruses (especially non-A, non-B, non-C hepatitis), parvovirus B19
            </td>
          </tr>
          <tr>
            <td><strong>Radiation</strong></td>
            <td>Ionizing radiation exposure</td>
          </tr>
          <tr>
            <td><strong>Immune Disorders</strong></td>
            <td>Systemic lupus erythematosus (SLE), eosinophilic fasciitis</td>
          </tr>
          <tr>
            <td><strong>Pregnancy</strong></td>
            <td>Rare, may remit after delivery</td>
          </tr>
        </table>

        <p><strong>Inherited Aplastic Anaemia (rare):</strong></p>
        <ul>
          <li><strong>Fanconi anaemia:</strong> Autosomal recessive, associated with short stature, skeletal abnormalities, café-au-lait spots, renal abnormalities, increased cancer risk. Usually presents in childhood but can present in young adults</li>
          <li><strong>Dyskeratosis congenita:</strong> X-linked or autosomal, characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, pulmonary fibrosis</li>
          <li><strong>Shwachman-Diamond syndrome:</strong> Autosomal recessive, pancreatic insufficiency, skeletal abnormalities</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>3. Clinical Presentation</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p>Clinical features depend on which cell line is most severely affected:</p>

        <table>
          <tr>
            <th>Cell Line Deficiency</th>
            <th>Clinical Features</th>
          </tr>
          <tr>
            <td><strong>Anaemia<br>(Low RBCs)</strong></td>
            <td>
              <ul>
                <li>Fatigue, lethargy, weakness</li>
                <li>Dyspnoea on exertion</li>
                <li>Pallor, conjunctival pallor</li>
                <li>Tachycardia, flow murmur</li>
                <li>Dizziness, headache</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Leukopenia<br>(Low WBCs)</strong></td>
            <td>
              <ul>
                <li>Recurrent or severe infections</li>
                <li>Bacterial infections (especially neutropenia)</li>
                <li>Fungal infections (oral candidiasis)</li>
                <li>Mouth ulcers, gingivitis</li>
                <li>Pneumonia, sepsis</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Thrombocytopenia<br>(Low Platelets)</strong></td>
            <td>
              <ul>
                <li>Easy bruising, petechiae, purpura</li>
                <li>Mucosal bleeding (epistaxis, gum bleeding)</li>
                <li>Menorrhagia</li>
                <li>GI bleeding, haematuria (severe cases)</li>
                <li>Intracranial haemorrhage (rare but life-threatening)</li>
              </ul>
            </td>
          </tr>
        </table>

        <p><strong>Important Examination Findings:</strong></p>
        <ul>
          <li><strong>NO hepatosplenomegaly or lymphadenopathy</strong> (absence is KEY - presence suggests alternative diagnosis like leukaemia or lymphoma)</li>
          <li>Pallor</li>
          <li>Petechiae, purpura, ecchymoses</li>
          <li>Signs of infection</li>
          <li>Look for congenital abnormalities if inherited cause suspected</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>4. Investigations and Diagnosis</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Essential Investigations:</strong></p>

        <p><strong>1. Full Blood Count (FBC):</strong></p>
        <ul>
          <li><strong>Pancytopenia</strong> affecting all three cell lines</li>
          <li>Anaemia - usually normocytic normochromic</li>
          <li>Leukopenia with neutropenia</li>
          <li>Thrombocytopenia</li>
          <li><strong>Low reticulocyte count</strong> (indicates bone marrow not responding appropriately to anaemia)</li>
        </ul>

        <p><strong>2. Blood Film:</strong></p>
        <ul>
          <li>Confirms pancytopenia</li>
          <li>Normal morphology of remaining cells</li>
          <li><strong>No abnormal/blast cells</strong> (helps exclude leukaemia)</li>
        </ul>

        <p><strong>3. Bone Marrow Biopsy (ESSENTIAL for diagnosis):</strong></p>
        <ul>
          <li><strong>Hypocellular marrow</strong> (usually <25% cellularity, often <10%)</li>
          <li>Increased fat spaces replacing haematopoietic tissue</li>
          <li>Reduced/absent megakaryocytes, erythroid and myeloid precursors</li>
          <li>No malignant infiltration, fibrosis, or dysplasia</li>
        </ul>

        <p><strong>4. Additional Tests to Identify Cause:</strong></p>
        <ul>
          <li>Viral screens: EBV, CMV, HIV, hepatitis (A, B, C), parvovirus B19</li>
          <li>Autoimmune screen: ANA, dsDNA (if SLE suspected)</li>
          <li>Vitamin B12 and folate (to exclude other causes of pancytopenia)</li>
          <li>Flow cytometry to exclude PNH (paroxysmal nocturnal haemoglobinuria) - CD55 and CD59 deficiency</li>
          <li>Chromosome breakage test if Fanconi anaemia suspected</li>
          <li>HLA typing (if transplant candidate)</li>
        </ul>

        <p><strong>5. Imaging:</strong></p>
        <ul>
          <li>Chest X-ray if infection suspected</li>
          <li>CT if invasive fungal infection suspected</li>
        </ul>

        <p><strong>Diagnostic Criteria for Aplastic Anaemia:</strong></p>
        <p>Requires presence of at least <strong>two of three</strong> peripheral blood criteria:</p>
        <ul>
          <li>Haemoglobin <100 g/L</li>
          <li>Platelet count <50 × 10⁹/L</li>
          <li>Neutrophil count <1.5 × 10⁹/L</li>
        </ul>
        <p><strong>PLUS</strong> hypocellular bone marrow on biopsy</p>
      </div>
    </div>

    <div class="question">
      <h3>5. Severity Classification</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p>Severity classification is based on peripheral blood counts and bone marrow cellularity. This has important prognostic and therapeutic implications.</p>

        <table>
          <tr>
            <th>Severity</th>
            <th>Bone Marrow Cellularity</th>
            <th>Peripheral Blood Criteria (≥2 of the following)</th>
          </tr>
          <tr>
            <td><strong>Non-Severe</strong></td>
            <td>Hypocellular</td>
            <td>
              Does not meet criteria for severe AA
            </td>
          </tr>
          <tr>
            <td><strong>Severe AA (SAA)</strong></td>
            <td><25% cellularity<br>(or 25-50% with <30% haematopoietic cells)</td>
            <td>
              <ul>
                <li>Neutrophils <0.5 × 10⁹/L</li>
                <li>Platelets <20 × 10⁹/L</li>
                <li>Reticulocytes <20 × 10⁹/L</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Very Severe AA (vSAA)</strong></td>
            <td>As per SAA</td>
            <td>
              As per SAA PLUS<br>
              <strong>Neutrophils <0.2 × 10⁹/L</strong>
            </td>
          </tr>
        </table>

        <p><strong>Prognostic Significance:</strong></p>
        <ul>
          <li><strong>Severe and very severe AA:</strong> High mortality without treatment (50% 1-year mortality). Require urgent specialist referral and aggressive treatment</li>
          <li><strong>Non-severe AA:</strong> May have more indolent course but still requires treatment and monitoring</li>
          <li><strong>Neutrophil count is the most important prognostic factor</strong> - severe neutropenia (<0.5) associated with high infection risk and mortality</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>6. Management</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>IMMEDIATE ACTIONS - Haematological Emergency:</strong></p>
        <ul>
          <li><strong>Urgent haematology referral</strong> (same day for severe/very severe AA)</li>
          <li>Admit to hospital if severe neutropenia or thrombocytopenia</li>
          <li>Isolate if neutropenic (single room, protective environment)</li>
          <li>Avoid IM injections (bleeding risk)</li>
          <li><strong>AVOID unnecessary transfusions before transplant assessment</strong> (alloimmunization reduces transplant success)</li>
        </ul>

        <p><strong>Supportive Care:</strong></p>
        <ul>
          <li><strong>Transfusion support:</strong>
            <ul>
              <li>Red cell transfusions for symptomatic anaemia (keep Hb >70-80 g/L)</li>
              <li>Platelet transfusions for bleeding or very low counts (<10 × 10⁹/L)</li>
              <li>Use irradiated, leukodepleted blood products (reduce CMV transmission and alloimmunization)</li>
              <li>Use single-donor platelets if transplant candidate</li>
            </ul>
          </li>
          <li><strong>Infection prevention and treatment:</strong>
            <ul>
              <li>Neutropenic precautions (hand hygiene, avoid crowded areas, avoid raw food)</li>
              <li>Prophylactic antibiotics (fluoroquinolone) if prolonged neutropenia</li>
              <li>Antifungal prophylaxis (fluconazole or posaconazole)</li>
              <li>Antibiotic therapy for neutropenic sepsis (broad-spectrum, e.g., piperacillin-tazobactam)</li>
              <li>G-CSF (granulocyte colony-stimulating factor) may be used short-term for severe infections but NOT routinely</li>
            </ul>
          </li>
          <li><strong>Remove causative agent</strong> if identified (stop offending drug, avoid toxin exposure)</li>
        </ul>

        <p><strong>Definitive Treatment:</strong></p>

        <p><strong>1. Haematopoietic Stem Cell Transplantation (HSCT):</strong></p>
        <ul>
          <li><strong>First-line for young patients (<40 years) with severe/very severe AA and matched sibling donor</strong></li>
          <li>Curative treatment with 75-90% long-term survival</li>
          <li>HLA typing of patient and siblings should be performed urgently</li>
          <li>Risks: Graft failure (5-10%), graft-versus-host disease (GVHD), infections, late effects</li>
          <li>Conditioning regimen: Cyclophosphamide + ATG ± radiotherapy</li>
          <li>Matched unrelated donor (MUD) transplant considered if no sibling donor and age <40-50 years</li>
        </ul>

        <p><strong>2. Immunosuppressive Therapy (IST):</strong></p>
        <ul>
          <li><strong>For patients not eligible for transplant:</strong> Older age (>40), no matched donor, patient preference</li>
          <li><strong>Standard regimen:</strong>
            <ul>
              <li><strong>Anti-thymocyte globulin (ATG):</strong> Horse ATG preferred over rabbit ATG</li>
              <li><strong>Cyclosporine:</strong> For 6-12 months, often longer</li>
            </ul>
          </li>
          <li>Response rate: 60-70% achieve transfusion independence</li>
          <li>Response usually seen by 3-6 months</li>
          <li>Risks: Serum sickness, infections, relapse (30-40%), clonal evolution to MDS/AML (10-15% at 10 years)</li>
          <li>May add eltrombopag (thrombopoietin receptor agonist) to improve response rates</li>
        </ul>

        <p><strong>3. Second-line Treatment:</strong></p>
        <ul>
          <li>Repeat course of IST</li>
          <li>Alternative donor HSCT (MUD or haploidentical)</li>
          <li>Eltrombopag monotherapy</li>
        </ul>

        <p><strong>Treatment Algorithm:</strong></p>
        <pre>
Severe/Very Severe AA
        ↓
Age <40 + Matched Sibling Donor?
        ↓
   YES → HSCT (first-line)
        ↓
   NO → IST (ATG + Cyclosporine ± Eltrombopag)
        ↓
   No response at 6 months or relapse
        ↓
   Consider: Repeat IST, MUD transplant, or Eltrombopag
        </pre>

        <p><strong>Long-term Monitoring:</strong></p>
        <ul>
          <li>Regular FBC monitoring</li>
          <li>Monitor for relapse</li>
          <li>Monitor for clonal evolution (MDS, PNH, AML) - annual bone marrow if IST-treated</li>
          <li>PNH screening (flow cytometry) as PNH can develop in AA patients</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>7. Differential Diagnosis</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p>Other causes of pancytopenia to consider:</p>

        <table>
          <tr>
            <th>Condition</th>
            <th>Distinguishing Features</th>
          </tr>
          <tr>
            <td><strong>Acute Leukaemia</strong></td>
            <td>Blast cells on film/marrow, HYPERcellular marrow with abnormal cells</td>
          </tr>
          <tr>
            <td><strong>Myelodysplastic Syndrome (MDS)</strong></td>
            <td>Dysplastic changes, variable cellularity, cytogenetic abnormalities</td>
          </tr>
          <tr>
            <td><strong>Hairy Cell Leukaemia</strong></td>
            <td>Splenomegaly, hairy cells on film, positive tartrate-resistant acid phosphatase (TRAP)</td>
          </tr>
          <tr>
            <td><strong>Hypersplenism</strong></td>
            <td>Splenomegaly, pooling/destruction in spleen, normal/hypercellular marrow</td>
          </tr>
          <tr>
            <td><strong>Megaloblastic Anaemia (severe)</strong></td>
            <td>Macrocytosis, hypersegmented neutrophils, megaloblastic marrow, low B12/folate</td>
          </tr>
          <tr>
            <td><strong>Bone Marrow Infiltration</strong></td>
            <td>
              Lymphoma, myeloma, metastatic carcinoma - abnormal cells on marrow, organomegaly common
            </td>
          </tr>
          <tr>
            <td><strong>Paroxysmal Nocturnal Haemoglobinuria (PNH)</strong></td>
            <td>Haemolytic anaemia, dark urine, thrombosis, flow cytometry (CD55/CD59 deficiency)</td>
          </tr>
          <tr>
            <td><strong>SLE</strong></td>
            <td>Multisystem features, autoimmune serology positive, normal/cellular marrow</td>
          </tr>
        </table>

        <p><strong>Key Points to Distinguish Aplastic Anaemia:</strong></p>
        <ul>
          <li><strong>Hypocellular bone marrow</strong> (not hypercellular like leukaemia)</li>
          <li><strong>No organomegaly</strong> (no hepatosplenomegaly or lymphadenopathy)</li>
          <li><strong>No abnormal cells</strong> on blood film or marrow</li>
          <li><strong>Normocytic anaemia</strong> (not macrocytic like B12/folate deficiency)</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>8. Prognosis and Complications</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Prognosis Without Treatment:</strong></p>
        <ul>
          <li><strong>Severe/Very Severe AA:</strong> ~50% mortality at 1 year, primarily from infection and bleeding</li>
          <li><strong>Non-severe AA:</strong> Better prognosis but progressive disease occurs in some</li>
        </ul>

        <p><strong>Prognosis With Treatment:</strong></p>
        <ul>
          <li><strong>HSCT (matched sibling):</strong> 75-90% long-term survival, best outcomes in young patients treated early</li>
          <li><strong>Immunosuppressive therapy:</strong> 60-70% achieve haematological response, 5-year survival ~75%</li>
        </ul>

        <p><strong>Complications:</strong></p>

        <p><strong>Acute Complications:</strong></p>
        <ul>
          <li><strong>Infection:</strong> Leading cause of death, particularly fungal and bacterial sepsis in severe neutropenia</li>
          <li><strong>Bleeding:</strong> Intracranial haemorrhage, GI bleeding in severe thrombocytopenia</li>
          <li><strong>Transfusion-related:</strong> Alloimmunization, iron overload (with chronic transfusions), transfusion reactions</li>
        </ul>

        <p><strong>Long-term Complications:</strong></p>
        <ul>
          <li><strong>Relapse:</strong> 30-40% after IST, usually within 2-5 years</li>
          <li><strong>Clonal evolution:</strong>
            <ul>
              <li>Myelodysplastic syndrome (MDS): 10-15% at 10 years</li>
              <li>Acute myeloid leukaemia (AML): 5-10% at 10 years</li>
              <li>Paroxysmal nocturnal haemoglobinuria (PNH): 10-20% develop PNH clone</li>
            </ul>
          </li>
          <li><strong>Transplant-related:</strong> Chronic GVHD, secondary malignancies, infertility, organ toxicity</li>
          <li><strong>Cyclosporine toxicity:</strong> Renal impairment, hypertension, gingival hyperplasia</li>
        </ul>

        <p><strong>Factors Associated with Better Prognosis:</strong></p>
        <ul>
          <li>Younger age</li>
          <li>Shorter duration of disease before treatment</li>
          <li>Higher baseline counts (especially neutrophils and platelets)</li>
          <li>Response to initial IST</li>
        </ul>
      </div>
    </div>

    <h2>Key Learning Points - Summary</h2>
    <div class="key-points">
      <ul>
        <li><strong>Aplastic anaemia</strong> is characterized by <strong>pancytopenia</strong> and <strong>hypocellular bone marrow</strong> due to failure of haematopoiesis</li>
        <li>Most cases are <strong>idiopathic (70%)</strong>, but important causes include drugs (chloramphenicol, NSAIDs), chemicals (benzene), viruses (hepatitis, EBV), and inherited syndromes (Fanconi anaemia)</li>
        <li>Clinical features reflect the deficiency of all three cell lines: <strong>anaemia (fatigue, pallor), neutropenia (infections), thrombocytopenia (bleeding/bruising)</strong></li>
        <li><strong>Absence of hepatosplenomegaly and lymphadenopathy</strong> is a KEY examination finding that helps distinguish AA from leukaemia/lymphoma</li>
        <li>Diagnosis requires <strong>bone marrow biopsy</strong> showing hypocellular marrow with <strong>no abnormal cells</strong></li>
        <li>Severity is classified based on blood counts with <strong>neutrophil count being the most important prognostic factor</strong></li>
        <li><strong>Treatment depends on age and donor availability:</strong>
          <ul>
            <li>Young patients (<40) with matched sibling donor → <strong>HSCT (first-line)</strong></li>
            <li>Older patients or no donor → <strong>Immunosuppressive therapy (ATG + Cyclosporine)</strong></li>
          </ul>
        </li>
        <li><strong>Urgent haematology referral</strong> is essential for severe/very severe AA - this is a haematological emergency</li>
        <li>Supportive care includes <strong>transfusion support, infection prevention, and neutropenic precautions</strong></li>
        <li>Long-term complications include <strong>relapse (30-40%), clonal evolution to MDS/AML (10-15%), and development of PNH</strong></li>
        <li>Prognosis without treatment is poor (50% 1-year mortality for severe AA), but with appropriate treatment, 75-90% long-term survival is achievable</li>
      </ul>
    </div>

    <h2>Further Learning Resources</h2>
    <ul>
      <li>British Society for Haematology Guidelines on Aplastic Anaemia</li>
      <li>Review bone marrow biopsy images comparing normal, hypocellular (aplastic anaemia), and hypercellular (leukaemia) marrow</li>
      <li>Research the pathophysiology of Fanconi anaemia and understand why it predisposes to aplastic anaemia and malignancy</li>
      <li>Compare and contrast aplastic anaemia with myelodysplastic syndrome (MDS)</li>
      <li>Review the mechanism of action of anti-thymocyte globulin (ATG) and why it works in aplastic anaemia</li>
    </ul>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        }
      }
    }// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          }
        }, 100);
      }
    });
    }
  </script>

</body>
</html>
